Pfizer Inc. (PFE)
Pre-market:
| Previous close | 27.77 |
| Open | 27.70 |
| Bid | 27.93 x 3100 |
| Ask | 0.00 x 3200 |
| Day's range | 27.52 - 28.34 |
| 52-week range | 25.20 - 40.37 |
| Volume | |
| Avg. volume | 42,623,340 |
| Market cap | 160.195B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.05 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | 1.68 (5.94%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | 31.37 |
BenzingaSecond Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy. The boy was enrolled in Phase 2 DAYLIGHT study studying the treatment in boys at least two years old and under four years old. The patient received the investigational gene therapy, fordadistrogene movaparvovec (PF-06939926), in early 2023. Citing Pfizer, Reuters
Investor's Business DailyPfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Pfizer stock ran up to its 50-day line after the company reported better-than-expected sales and profit. Is PFE stock a buy?
Insider MonkeyOPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript May 7, 2024 OPKO Health, Inc. misses on earnings expectations. Reported EPS is $-0.11577 EPS, expectations were $-0.09. OPKO Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and […]
